Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.84 USD
Change Today -0.89 / -3.92%
Volume 226.6K
QDEL On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Open
$22.72
Previous Close
$22.73
Day High
$22.88
Day Low
$21.39
52 Week High
01/8/15 - $29.38
52 Week Low
07/10/14 - $20.65
Market Cap
753.3M
Average Volume 10 Days
145.3K
EPS TTM
$0.05
Shares Outstanding
34.5M
EX-Date
--
P/E TM
445.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia Respiratory Syncytial Virus (RSV) and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

610 Employees
Last Reported Date: 02/24/15
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $524.4K
Chief Financial Officer
Total Annual Compensation: $331.9K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $322.7K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Research and Develop...
Total Annual Compensation: $195.5K
Compensation as of Fiscal Year 2014.

quidel corp (QDEL) Key Developments

Quidel Corporation Approves Amendment of the Restated Certificate of Incorporation

Quidel Corporation approved the amendment of the Restated Certificate of Incorporation to increase the number of authorized shares of capital stock at the Annual Meeting of Stockholders held on May 5, 2015.

Quidel Corp. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:00 PM

Quidel Corp. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Douglas C. Bryant, Chief Executive Officer, President and Director.

Quidel Corporation Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Provides Effective Tax Rate Guidance for the Full Year of 2015

Quidel Corporation reported unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $61,302,000 compared to $46,673,000 a year ago. Operating income was $8,689,000 against operating loss of $2,016,000 a year ago. Income before taxes was $5,794,000 against loss before taxes of $2,376,000 a year ago. Net income was $3,991,000 or $0.11 per diluted share against net loss of $1,512,000 or $0.04 per diluted share a year ago. on a non-GAAP basis, excluding amortization of intangibles, stock compensation expense and certain non-recurring items, net income was $10.8 million, or $0.30 per diluted share compared to $2.9 million or $0.08 per diluted share for the same period in 2014. The increase in revenue was due primarily to greater sales of infectious disease products in the first quarter of 2015 as well as growth across all major categories. Operating activities provided $31.8 million of cash and purchase of property and equipment used $2.9 million in the quarter. Tax rate for the first quarter was approximately 31%. The effective tax rate is lower compared to the first quarter of 2014, mostly due to the change in valuation allowance related to certain state deferred tax assets. For the full year, the company expects effective tax rate to be approximately the same. Spend to research and developments will be in the previously communicated range of $40 million to $42 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $21.84 USD -0.89

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $86.77 USD -0.72
GenMark Diagnostics Inc $9.04 USD +0.01
Luminex Corp $16.45 USD -0.18
Meridian Bioscience Inc $18.27 USD -0.34
OraSure Technologies Inc $6.60 USD +0.18
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 3.0x
Price/Cash Flow 103.9x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.